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 r  t  i  c  l  e  i  n  f  orticle history:
ulocyte maturation by the intensity of the staining of reticu-
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he article on the evaluation of the effectiveness of mature
ed cell and reticulocyte parameters under three conditions:
ron deﬁciency anemia, anemia of chronic disease (ACD),
nd anemia of chronic disease associated with absolute iron
eﬁciency by Torino et al.1 is very valuable. Automated retic-
locyte counts are widely used in the clinical laboratory due
o their greater precision, accuracy and reproducibility com-
ared to those obtained using the microscope. The most
mportant beneﬁt of automated methods is the greater pre-
ision of counts. By analyzing a much greater number of
eticulocytes (more than ten thousand), the statistical error
s minimized.2 Visual microscopy is still recommended as
he comparability method for reticulocytes, despite stud-
es showing that the variation coefﬁcient (VC) ranges from
0% to 40%. Fully automated methods have eliminated
nter-observer variability and subjectivity and substantially
educed turnaround time. Automated methods employ a
ide variety of reagents for reticulocyte RNA and these
how different sensitivity on binding to RNA.3 Therefore,
lthough automated ﬂow cytometric analysis has led to a
igniﬁcant advance in reticulocyte counting, some limita-
ions still persist in comparability across different laboratories
 See paper by Torino et al. on pages 77–81.
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eserved.and better methods of standardization and harmoniza-
tion are needed.4 Nevertheless, biological and pre-analytical
variations can potentially affect test performance and the
clinical interpretation of laboratory results.5 Pre-analytical
variations represent a major source of inaccurate labora-
tory results. Reticulocyte counts are signiﬁcantly decreased
after 24 h of storage at room temperature due to in vitro
maturation of the reticulocytes. At constant temperatures
of 4 ◦C the counts remain unchanged, with certain limi-
tations for parameters derived or calculated from cellular
volumes.6,7
Automated reticulocyte counts not only provide enhanced
precision and accuracy, but also perform reliable measure-
ments of mRNA  content and of cellular indices such as
volume, hemoglobin concentration and content. These novel
parameters have prompted interest and studies regarding
their clinical usefulness, the utility of reporting and their inter-
pretation. Immature reticulocyte fraction (IRF) assesses retic-ienda Ospedaliera-Università di Padova, Via Nicolò Giustiniani 2,
locytes, which reﬂects mRNA  content. IRF seems to be useful
for the evaluation of engraftment in bone marrow or stem cell
transplantation.9
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights
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IRF has been proposed as an early marker of engraftment
in bone marrow or hematopoietic stem cell transplantation
and bone marrow regeneration following chemotherapy.10
Several studies have demonstrated that increases in the IRF
are an indicator of engraftment and precede other param-
eters, such as absolute neutrophil counts (ANC), reticulated
platelet or reticulocyte counts.11,12 Thus, changes in IRF during
erythropoiesis-stimulating agent (ESA) therapy are indica-
tive of the effectiveness of stimulation.13 Many authors have
reported data concerning the clinical utility of IRF in the diag-
nosis and monitoring of anemia.14,15 IRF in conjunction with
the reticulocyte count, provides essentially the same infor-
mation as the reticulocyte production index (RPI), making its
manual calculation unnecessary. The clinical utility of IRF
has been reported in a variety of conditions such as in the
monitoring of anemia treatment, neonatal transfusion needs,
prognosis in prematurity, in AIDS anemia, renal transplant
engraftment due to erythropoietin production, the detection
of occult or compensated hemorrhages or hemolysis, aplastic
crisis in hemolytic anemias and to verify aplastic anemia.16
The IRF is a promising parameter that needs consolidation
into the clinical practice.
Mean reticulocyte hemoglobin, a measurement of the Hb
content of reticulocytes expressed in pg/cell was ﬁrst mea-
sured using Bayer H3 instruments and abbreviated as CHr.17,18
CHr is the product of the cellular volume and the cellu-
lar hemoglobin concentration. Mean reticulocyte hemoglobin
has become available in other fully automated hemato-
logy analyzers that provide reticulocyte count and maturity.
The methodology developed by Sysmex (Sysmex Corpora-
tion, Kobe, Japan) for the XE and later for the XN series of
automated hematology analyzers provides the reticulocyte
hemoglobin or Ret-He parameter, formerly deﬁned as RET-Y.
The mean hemoglobin content of reticulocytes (MCHr) and
the mean hemoglobin concentration of reticulocytes (CHCr)
have become available in the CELL-DYN Sapphire analyzer of
Abbott (Abbott Diagnostics, Santa Clara, CA, USA). The reticu-
locyte hemoglobin expression (RHE) is available in the BC 6800
Mindray analyzer for research use only (Mindray BioMedical
Electronics Co, Shenzhen, P.R. China), while the reticulocyte
hemoglobin cellular content (RHCc) is provided in the new
generation of Pentra blood cell analytical systems (Horiba
Medical, Montpellier Cedex, France). RHE and RHCc need to
be evaluated and comparison studies should be assessed to
verify if the new indices are close to those obtained by other
instruments, thus providing reliable results.
Beckman Coulter (Beckman Coulter Inc) provides a new
parameter, the red blood cell size factor (RSf), which seems
to be in agreement with CHr. The RSf parameter, expressed in
fL, joins together the volume of mature red cells (MCV) and
the volume of reticulocytes (MRV), according to the following
mathematical formula: RSf =
√
(MCV × MVR).19
Since the life span of the reticulocytes is four days,
the measurement of reticulocyte hemoglobin content can
directly reﬂect the functional availability of iron in that time
frame.20 Reticulocyte hemoglobin content is a reliable and
early indicator of bone marrow iron status and may detect
functional iron deﬁciency with more  sensitivity than bio-
chemical parameters.21 Reticulocyte hemoglobin content may
optimize IV iron therapy and indicate the efﬁcacy of responsesr. 2 0 1 5;3 7(2):73–76
to anemia treatment at an early stage. Although its reduction
reﬂects the impairment of hemoglobin production, reticulo-
cyte hemoglobin content is not the appropriate measure to
assess iron adequacy in the presence of genetic microcytosis
such as thalassemia.22,23 Iron-sequestration syndromes occur
in chronic diseases when iron is not available for erythro-
poiesis, due to inappropriately high serum hepcidin values,
which determine iron sequestration in reticuloendothelial
system macrophages.24 One of the major determinants of the
anemia of chronic disease is iron sequestration.24–27
Several studies have assessed the value of reticulocyte
hemoglobin in conjunction with other parameters to diagnose
iron deﬁciency states. Other studies have assessed the use
of both hepcidin and reticulocyte hemoglobin in ACD. Serum
hepcidin was shown not to be clinically useful or superior
to more  standard iron status tests, for managing iron ther-
apy in HD patients on ESA treatment; reticulocyte hemoglobin
content and percentage of hypochromic red blood cells were
shown to be more  useful, either alone or in combination with
the transferrin saturation ratio and ferritin levels.28–30
The clinical utility of reticulocyte hemoglobin content has
been well established as a reliable marker of functional iron
deﬁciency in hemodialysis patients, exhibiting high speci-
ﬁcity and sensitivity in the management of IV iron therapy.
In patients with chronic kidney diseases and anemia that
are undergoing ESA treatment, repletion of iron stores should
be ensured before and during therapy. Iron levels must be
adequate to optimize hemoglobin production in a balance
with erythropoiesis stimulation.31 The Kidney Disease Out-
comes Quality Initiative (NKF KDOQI)TM of the National Kidney
Foundation has provided evidence-based clinical practice
guidelines where CHr is considered an appropriate test to
assess adequacy of iron for erythropoiesis.32 In the British
Guidelines for Laboratory Diagnosis of Functional Iron Deﬁ-
ciency, CHr is one of the recommended tests with a proposed
cut-off value of CHr <29 pg.33
The reticulocyte hemoglobin content presents some diag-
nostic limitations. The reticulocyte hemoglobin content is
decreased in thalassemia syndromes, where the reduction in
CHr seems to be correlated with the degree of impairment in
beta chain synthesis, and in other microcytic anemias due to
congenital hemoglobin diseases.34 It can also be elevated in
iron-deﬁcient patients with confounding megaloblastic ane-
mia  because of the high mean reticulocyte volume associated
with megaloblastosis.35 Therefore, it is important that CHr
values are interpreted in the context of the patient’s overall
erythrocyte physiology, including knowledge of recent blood
transfusions, iron therapy, vitamin B12 or folate deﬁciency,
chemotherapy and the results of hemoglobin analysis. Few
studies are available on the clinical utility of reticulocyte cell
volume however its usefulness seems to be similar to the
reticulocyte hemoglobin content in anemia evaluation and
monitoring.35
With the introduction of automated methods, it has
become mandatory to report the absolute count which gives
more accurate information on erythropoiesis than the simple
36counts have resulted in phasing out the old fashion “hema-
tocrit correction” of reticulocyte percentage. In addition, the
obsolete “reticulocyte production index”, that corrected the
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eticulocyte count both for Hct and maturation time, can be
eplaced with IRF, which offers the same clinical signiﬁcance.
Laboratories should report the reticulocyte count as the
bsolute number of reticulocytes, accompanied by properly
etermined and method-speciﬁc reference ranges. The per-
entage value may be optional, but it is still important in
onitoring bone marrow response when plasma volume is
uctuating as happens in blood boosting in athletes or in
idney diseases. The clinical utility of reticulocyte cellular
arameters such as IRF and reticulocyte hemoglobin content
as been proven, while MCVr may be optional, even though it
ould in some instances provide useful information. It may be
seful for laboratories to consider providing an interpretation
f the reticulocyte analysis. As an example, if the abso-
ute reticulocyte count and IRF are simultaneously increased,
n interpretative comment could be added to emphasize
he increase of erythropoietic activity. This comment could
elp physicians assess cases of suspected hemolytic ane-
ia  or in monitoring the treatment of anemia. In conclusion,
utomated reticulocyte counts provide acceptable precision
nd bias while parameters and indices improve the eval-
ation of erythropoiesis. Since a qualitative evaluation is
erformed with reticulocyte maturation parameters and cel-
ular indices, external quality assessment programs should
e provided, and interpretative reporting should be offered to
linicians.37,38 Nevertheless, standardization and harmoniza-
ion should be encouraged.
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